Tag: pembrolizuamb

1. 36-month overall survival was significantly greater in the pembrolizumab-chemoradiotherapy group compared to placebo-chemoradiotherapy. 2. Grade 3 or higher adverse ...

1. The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...

Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...